RxDoctor Payments Data

Roque Anthony Velasco, NP

Nurse Practitioner · Palm Springs, CANPI 1710431614

Payments from drug & device makers

$13,251in general payments, 2019–2025

Across 80 payments — averaging $165.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$11K
  • Viiv Healthcare Company$1K
  • Theratechnologies Inc.$421
  • Janssen Products, LP$331
  • Napo Pharmaceuticals Inc$315
  • Merck$171
  • plus $89 from 2 others

What the payments were for

  • Consulting fees$7,04053%
  • Speaking & faculty fees$1191%
  • Travel & lodging$2,25317%
  • Food & beverage$3,56427%
  • Education$2752%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,251 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$4,940
Medicare patients
23
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala194$863,793
TivicayDolutegravir Sodium137$460,337
DovatoDolutegravir Sodium/Lamivudine141$451,937
JulucaDolutegravir/Rilpivirine92$417,020
DescovyEmtricitabine/Tenofov Alafenam131$379,189
GenvoyaElviteg/Cob/Emtri/Tenof Alafen56$249,118
PrezcobixDarunavir/Cobicistat80$226,660
CabenuvaCabotegravir/Rilpivirine25$161,361
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf27$143,741
TriumeqAbacavir/Dolutegravir/Lamivudi31$133,881
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$128,086
MytesiCrofelemer20$124,070
RukobiaFostemsavir Tromethamine14$119,881
Darunavir33$77,649
OzempicSemaglutide60$58,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Dovato, Juluca, Cabenuva, Triumeq$1,204$1,744,419440 claims
GileadBiktarvy, Descovy, Genvoya$10,719$1,492,100381 claims
Johnson & JohnsonPrezcobix$71$226,66080 claims
Janssen Products, LPSymtuza$331$143,74127 claims
Napo Pharmaceuticals IncMytesi$315$124,07020 claims
MerckIsentress, Januvia, Pifeltro$171$95,31754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →